Efficacy of pramipexole combined with madopar in treating patients with Parkison diseases and its influence on quality of life
10.7619/jcmp.201801015
- VernacularTitle:普拉克索联合美多巴治疗帕金森病的疗效及对生活质量的影响
- Author:
Ke XU
1
;
Yang ZHANG
;
Chunying OU
;
Xiaolei AN
;
Jing GUO
Author Information
1. 东南大学附属徐州中心医院神经内科
- Keywords:
madopar;
pramipexole;
Parkinson diseases;
quality of life
- From:
Journal of Clinical Medicine in Practice
2018;22(1):48-50,54
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of pramipexole combined with madopar in treating patients with Parkison diseases and its influence on quality of life.Methods Totally 90 patients with Parkison diseases were selected and divided into experimental group and control group.Patients in control group were treated with madopar,while patients in experimental group were treated with the combination of madopar and pramipexole.The UPDRS and HAMD were used to evaluate the mental conditions of patients,and the adverse reactions and the clinical efficacy were evaluated.Results The clinical effective rate of the experimental group was significantly better than control group,HAMD value of experimental group was significantly lower than control group,and UPDRS values were significantly higher than control group.There was no significant difference of the adverse reactions between the two groups.Conclusion The combination of madopar and pramipexole can effectively improve the clinical syndrome and quality of life in patients with Parkinson diseases.
